nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Vandetanib—thyroid cancer	0.31	0.487	CbGbCtD
Zoledronate—ABCC1—Epirubicin—thyroid cancer	0.214	0.335	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—thyroid cancer	0.114	0.178	CbGbCtD
Zoledronate—GGPS1—saliva-secreting gland—thyroid cancer	0.00945	0.143	CbGeAlD
Zoledronate—GGPS1—trachea—thyroid cancer	0.00729	0.11	CbGeAlD
Zoledronate—GGPS1—thyroid gland—thyroid cancer	0.00577	0.0871	CbGeAlD
Zoledronate—GGPS1—head—thyroid cancer	0.00512	0.0773	CbGeAlD
Zoledronate—FDPS—saliva-secreting gland—thyroid cancer	0.00436	0.0658	CbGeAlD
Zoledronate—GGPS1—lymph node—thyroid cancer	0.00358	0.0541	CbGeAlD
Zoledronate—CA12—trachea—thyroid cancer	0.0034	0.0513	CbGeAlD
Zoledronate—FDPS—trachea—thyroid cancer	0.00336	0.0508	CbGeAlD
Zoledronate—CA2—neck—thyroid cancer	0.0029	0.0438	CbGeAlD
Zoledronate—FDPS—thyroid gland—thyroid cancer	0.00266	0.0402	CbGeAlD
Zoledronate—CA12—head—thyroid cancer	0.00239	0.036	CbGeAlD
Zoledronate—FDPS—head—thyroid cancer	0.00236	0.0356	CbGeAlD
Zoledronate—GGPS1—Activation of gene expression by SREBF (SREBP)—RXRA—thyroid cancer	0.00234	0.126	CbGpPWpGaD
Zoledronate—CA2—saliva-secreting gland—thyroid cancer	0.00226	0.0342	CbGeAlD
Zoledronate—Risedronate—PTGS2—thyroid cancer	0.00221	0.529	CrCbGaD
Zoledronate—Clodronate—PTGS2—thyroid cancer	0.00197	0.471	CrCbGaD
Zoledronate—ABCC1—trachea—thyroid cancer	0.00195	0.0295	CbGeAlD
Zoledronate—GGPS1—Regulation of cholesterol biosynthesis by SREBP (SREBF)—RXRA—thyroid cancer	0.00187	0.101	CbGpPWpGaD
Zoledronate—CA2—trachea—thyroid cancer	0.00174	0.0264	CbGeAlD
Zoledronate—FDPS—lymph node—thyroid cancer	0.00165	0.025	CbGeAlD
Zoledronate—ABCC1—thyroid gland—thyroid cancer	0.00154	0.0233	CbGeAlD
Zoledronate—CA2—thyroid gland—thyroid cancer	0.00138	0.0209	CbGeAlD
Zoledronate—CA2—head—thyroid cancer	0.00122	0.0185	CbGeAlD
Zoledronate—FDPS—Activation of gene expression by SREBF (SREBP)—RXRA—thyroid cancer	0.001	0.0538	CbGpPWpGaD
Zoledronate—ABCC1—lymph node—thyroid cancer	0.000959	0.0145	CbGeAlD
Zoledronate—CA2—lymph node—thyroid cancer	0.000857	0.013	CbGeAlD
Zoledronate—ABCC1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000827	0.0444	CbGpPWpGaD
Zoledronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—RXRA—thyroid cancer	0.000799	0.0429	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000776	0.0417	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—MINPP1—thyroid cancer	0.000536	0.0288	CbGpPWpGaD
Zoledronate—Dermatitis—Vandetanib—thyroid cancer	0.000471	0.00172	CcSEcCtD
Zoledronate—Influenza like illness—Doxorubicin—thyroid cancer	0.000469	0.00171	CcSEcCtD
Zoledronate—Headache—Vandetanib—thyroid cancer	0.000468	0.00171	CcSEcCtD
Zoledronate—Candida infection—Doxorubicin—thyroid cancer	0.000461	0.00169	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000459	0.00168	CcSEcCtD
Zoledronate—Blood urea increased—Doxorubicin—thyroid cancer	0.000456	0.00167	CcSEcCtD
Zoledronate—GGPS1—Metabolism—NDUFA13—thyroid cancer	0.000456	0.0245	CbGpPWpGaD
Zoledronate—Dyspnoea—Sorafenib—thyroid cancer	0.000449	0.00164	CcSEcCtD
Zoledronate—Nausea—Vandetanib—thyroid cancer	0.000444	0.00162	CcSEcCtD
Zoledronate—Dyspepsia—Sorafenib—thyroid cancer	0.000444	0.00162	CcSEcCtD
Zoledronate—Oesophagitis—Doxorubicin—thyroid cancer	0.000441	0.00161	CcSEcCtD
Zoledronate—Decreased appetite—Sorafenib—thyroid cancer	0.000438	0.0016	CcSEcCtD
Zoledronate—Neoplasm—Doxorubicin—thyroid cancer	0.000437	0.0016	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000435	0.00159	CcSEcCtD
Zoledronate—Fatigue—Sorafenib—thyroid cancer	0.000434	0.00159	CcSEcCtD
Zoledronate—Constipation—Sorafenib—thyroid cancer	0.000431	0.00157	CcSEcCtD
Zoledronate—Pain—Sorafenib—thyroid cancer	0.000431	0.00157	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CHST14—thyroid cancer	0.000429	0.023	CbGpPWpGaD
Zoledronate—Eye pain—Epirubicin—thyroid cancer	0.00042	0.00153	CcSEcCtD
Zoledronate—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000412	0.00151	CcSEcCtD
Zoledronate—Renal failure acute—Epirubicin—thyroid cancer	0.00041	0.0015	CcSEcCtD
Zoledronate—FDPS—SREBP signalling—PPARG—thyroid cancer	0.000408	0.022	CbGpPWpGaD
Zoledronate—Urticaria—Sorafenib—thyroid cancer	0.0004	0.00146	CcSEcCtD
Zoledronate—Body temperature increased—Sorafenib—thyroid cancer	0.000398	0.00146	CcSEcCtD
Zoledronate—Abdominal pain—Sorafenib—thyroid cancer	0.000398	0.00146	CcSEcCtD
Zoledronate—Renal impairment—Epirubicin—thyroid cancer	0.000398	0.00146	CcSEcCtD
Zoledronate—Eye pain—Doxorubicin—thyroid cancer	0.000388	0.00142	CcSEcCtD
Zoledronate—Lethargy—Epirubicin—thyroid cancer	0.000387	0.00141	CcSEcCtD
Zoledronate—Renal failure acute—Doxorubicin—thyroid cancer	0.00038	0.00139	CcSEcCtD
Zoledronate—Pain in extremity—Epirubicin—thyroid cancer	0.000379	0.00138	CcSEcCtD
Zoledronate—Osteoarthritis—Epirubicin—thyroid cancer	0.000379	0.00138	CcSEcCtD
Zoledronate—Hypersensitivity—Sorafenib—thyroid cancer	0.000371	0.00136	CcSEcCtD
Zoledronate—Renal impairment—Doxorubicin—thyroid cancer	0.000368	0.00135	CcSEcCtD
Zoledronate—Asthenia—Sorafenib—thyroid cancer	0.000362	0.00132	CcSEcCtD
Zoledronate—Lethargy—Doxorubicin—thyroid cancer	0.000358	0.00131	CcSEcCtD
Zoledronate—Pruritus—Sorafenib—thyroid cancer	0.000356	0.0013	CcSEcCtD
Zoledronate—Blood creatinine increased—Epirubicin—thyroid cancer	0.000355	0.0013	CcSEcCtD
Zoledronate—Dehydration—Epirubicin—thyroid cancer	0.000352	0.00129	CcSEcCtD
Zoledronate—Osteoarthritis—Doxorubicin—thyroid cancer	0.000351	0.00128	CcSEcCtD
Zoledronate—Pain in extremity—Doxorubicin—thyroid cancer	0.000351	0.00128	CcSEcCtD
Zoledronate—Abdominal pain upper—Epirubicin—thyroid cancer	0.000346	0.00126	CcSEcCtD
Zoledronate—GGPS1—Metabolism—HPGD—thyroid cancer	0.000346	0.0186	CbGpPWpGaD
Zoledronate—Hypokalaemia—Epirubicin—thyroid cancer	0.000345	0.00126	CcSEcCtD
Zoledronate—Diarrhoea—Sorafenib—thyroid cancer	0.000345	0.00126	CcSEcCtD
Zoledronate—Nasopharyngitis—Epirubicin—thyroid cancer	0.000339	0.00124	CcSEcCtD
Zoledronate—Gastritis—Epirubicin—thyroid cancer	0.000335	0.00123	CcSEcCtD
Zoledronate—Muscular weakness—Epirubicin—thyroid cancer	0.000334	0.00122	CcSEcCtD
Zoledronate—Dizziness—Sorafenib—thyroid cancer	0.000333	0.00122	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000331	0.0178	CbGpPWpGaD
Zoledronate—Abdominal distension—Epirubicin—thyroid cancer	0.00033	0.0012	CcSEcCtD
Zoledronate—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000328	0.0012	CcSEcCtD
Zoledronate—Influenza—Epirubicin—thyroid cancer	0.000327	0.0012	CcSEcCtD
Zoledronate—Dysphagia—Epirubicin—thyroid cancer	0.000327	0.0012	CcSEcCtD
Zoledronate—Asthma—Epirubicin—thyroid cancer	0.000327	0.0012	CcSEcCtD
Zoledronate—Dehydration—Doxorubicin—thyroid cancer	0.000326	0.00119	CcSEcCtD
Zoledronate—ABCC1—S1P1 pathway—PTGS2—thyroid cancer	0.000322	0.0173	CbGpPWpGaD
Zoledronate—Vomiting—Sorafenib—thyroid cancer	0.00032	0.00117	CcSEcCtD
Zoledronate—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00032	0.00117	CcSEcCtD
Zoledronate—Hypokalaemia—Doxorubicin—thyroid cancer	0.000319	0.00117	CcSEcCtD
Zoledronate—Rash—Sorafenib—thyroid cancer	0.000318	0.00116	CcSEcCtD
Zoledronate—Dermatitis—Sorafenib—thyroid cancer	0.000317	0.00116	CcSEcCtD
Zoledronate—Headache—Sorafenib—thyroid cancer	0.000316	0.00115	CcSEcCtD
Zoledronate—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000313	0.00115	CcSEcCtD
Zoledronate—Pancytopenia—Epirubicin—thyroid cancer	0.000311	0.00114	CcSEcCtD
Zoledronate—Gastritis—Doxorubicin—thyroid cancer	0.00031	0.00113	CcSEcCtD
Zoledronate—Muscular weakness—Doxorubicin—thyroid cancer	0.000309	0.00113	CcSEcCtD
Zoledronate—Neutropenia—Epirubicin—thyroid cancer	0.000306	0.00112	CcSEcCtD
Zoledronate—Abdominal distension—Doxorubicin—thyroid cancer	0.000305	0.00111	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000304	0.00111	CcSEcCtD
Zoledronate—Influenza—Doxorubicin—thyroid cancer	0.000303	0.00111	CcSEcCtD
Zoledronate—Asthma—Doxorubicin—thyroid cancer	0.000303	0.00111	CcSEcCtD
Zoledronate—Dysphagia—Doxorubicin—thyroid cancer	0.000303	0.00111	CcSEcCtD
Zoledronate—Pollakiuria—Epirubicin—thyroid cancer	0.000303	0.00111	CcSEcCtD
Zoledronate—Nausea—Sorafenib—thyroid cancer	0.000299	0.00109	CcSEcCtD
Zoledronate—Weight increased—Epirubicin—thyroid cancer	0.000298	0.00109	CcSEcCtD
Zoledronate—Weight decreased—Epirubicin—thyroid cancer	0.000296	0.00108	CcSEcCtD
Zoledronate—Infestation—Epirubicin—thyroid cancer	0.000292	0.00107	CcSEcCtD
Zoledronate—Infestation NOS—Epirubicin—thyroid cancer	0.000292	0.00107	CcSEcCtD
Zoledronate—Pancytopenia—Doxorubicin—thyroid cancer	0.000288	0.00105	CcSEcCtD
Zoledronate—Renal failure—Epirubicin—thyroid cancer	0.000287	0.00105	CcSEcCtD
Zoledronate—Stomatitis—Epirubicin—thyroid cancer	0.000285	0.00104	CcSEcCtD
Zoledronate—Conjunctivitis—Epirubicin—thyroid cancer	0.000284	0.00104	CcSEcCtD
Zoledronate—Urinary tract infection—Epirubicin—thyroid cancer	0.000284	0.00104	CcSEcCtD
Zoledronate—Neutropenia—Doxorubicin—thyroid cancer	0.000283	0.00104	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000282	0.00103	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00028	0.0151	CbGpPWpGaD
Zoledronate—Pollakiuria—Doxorubicin—thyroid cancer	0.00028	0.00102	CcSEcCtD
Zoledronate—Haematuria—Epirubicin—thyroid cancer	0.000278	0.00102	CcSEcCtD
Zoledronate—Weight increased—Doxorubicin—thyroid cancer	0.000276	0.00101	CcSEcCtD
Zoledronate—Weight decreased—Doxorubicin—thyroid cancer	0.000274	0.001	CcSEcCtD
Zoledronate—Agranulocytosis—Epirubicin—thyroid cancer	0.000272	0.000996	CcSEcCtD
Zoledronate—Infestation NOS—Doxorubicin—thyroid cancer	0.00027	0.000987	CcSEcCtD
Zoledronate—Infestation—Doxorubicin—thyroid cancer	0.00027	0.000987	CcSEcCtD
Zoledronate—Bradycardia—Epirubicin—thyroid cancer	0.000267	0.000975	CcSEcCtD
Zoledronate—Renal failure—Doxorubicin—thyroid cancer	0.000266	0.000971	CcSEcCtD
Zoledronate—Stomatitis—Doxorubicin—thyroid cancer	0.000263	0.000963	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—thyroid cancer	0.000263	0.00096	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—thyroid cancer	0.000263	0.00096	CcSEcCtD
Zoledronate—CA14—Metabolism—MINPP1—thyroid cancer	0.000262	0.0141	CbGpPWpGaD
Zoledronate—Hypoaesthesia—Epirubicin—thyroid cancer	0.000261	0.000953	CcSEcCtD
Zoledronate—Urinary tract disorder—Epirubicin—thyroid cancer	0.000259	0.000946	CcSEcCtD
Zoledronate—Oedema peripheral—Epirubicin—thyroid cancer	0.000258	0.000944	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—thyroid cancer	0.000258	0.000942	CcSEcCtD
Zoledronate—Connective tissue disorder—Epirubicin—thyroid cancer	0.000258	0.000941	CcSEcCtD
Zoledronate—Urethral disorder—Epirubicin—thyroid cancer	0.000257	0.000939	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—thyroid cancer	0.000252	0.000922	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—thyroid cancer	0.000247	0.000902	CcSEcCtD
Zoledronate—Eye disorder—Epirubicin—thyroid cancer	0.000245	0.000895	CcSEcCtD
Zoledronate—Flushing—Epirubicin—thyroid cancer	0.000243	0.000889	CcSEcCtD
Zoledronate—Cardiac disorder—Epirubicin—thyroid cancer	0.000243	0.000889	CcSEcCtD
Zoledronate—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000241	0.000882	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00024	0.000875	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—thyroid cancer	0.000239	0.000873	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000238	0.000871	CcSEcCtD
Zoledronate—Angiopathy—Epirubicin—thyroid cancer	0.000238	0.000869	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—thyroid cancer	0.000238	0.000869	CcSEcCtD
Zoledronate—Immune system disorder—Epirubicin—thyroid cancer	0.000237	0.000865	CcSEcCtD
Zoledronate—Mediastinal disorder—Epirubicin—thyroid cancer	0.000236	0.000863	CcSEcCtD
Zoledronate—Chills—Epirubicin—thyroid cancer	0.000235	0.00086	CcSEcCtD
Zoledronate—Arrhythmia—Epirubicin—thyroid cancer	0.000234	0.000856	CcSEcCtD
Zoledronate—Alopecia—Epirubicin—thyroid cancer	0.000232	0.000847	CcSEcCtD
Zoledronate—Mental disorder—Epirubicin—thyroid cancer	0.00023	0.000839	CcSEcCtD
Zoledronate—FDPS—Metabolism—MINPP1—thyroid cancer	0.000229	0.0123	CbGpPWpGaD
Zoledronate—Malnutrition—Epirubicin—thyroid cancer	0.000228	0.000834	CcSEcCtD
Zoledronate—Erythema—Epirubicin—thyroid cancer	0.000228	0.000834	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—thyroid cancer	0.000227	0.000828	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—thyroid cancer	0.000225	0.000823	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—thyroid cancer	0.000225	0.000823	CcSEcCtD
Zoledronate—Dysgeusia—Epirubicin—thyroid cancer	0.000223	0.000817	CcSEcCtD
Zoledronate—CA14—Metabolism—NDUFA13—thyroid cancer	0.000223	0.012	CbGpPWpGaD
Zoledronate—Back pain—Epirubicin—thyroid cancer	0.000221	0.000807	CcSEcCtD
Zoledronate—CA12—Metabolism—MINPP1—thyroid cancer	0.000221	0.0119	CbGpPWpGaD
Zoledronate—Angiopathy—Doxorubicin—thyroid cancer	0.00022	0.000804	CcSEcCtD
Zoledronate—Muscle spasms—Epirubicin—thyroid cancer	0.000219	0.000802	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—thyroid cancer	0.000219	0.000801	CcSEcCtD
Zoledronate—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000219	0.000799	CcSEcCtD
Zoledronate—Chills—Doxorubicin—thyroid cancer	0.000218	0.000795	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—thyroid cancer	0.000217	0.000792	CcSEcCtD
Zoledronate—Vision blurred—Epirubicin—thyroid cancer	0.000215	0.000786	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—thyroid cancer	0.000214	0.000783	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—thyroid cancer	0.000212	0.000777	CcSEcCtD
Zoledronate—Ill-defined disorder—Epirubicin—thyroid cancer	0.000212	0.000774	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—thyroid cancer	0.000211	0.000772	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—thyroid cancer	0.000211	0.000772	CcSEcCtD
Zoledronate—Anaemia—Epirubicin—thyroid cancer	0.000211	0.000771	CcSEcCtD
Zoledronate—Agitation—Epirubicin—thyroid cancer	0.00021	0.000766	CcSEcCtD
Zoledronate—CA14—Metabolism—CHST14—thyroid cancer	0.000209	0.0113	CbGpPWpGaD
Zoledronate—Dysgeusia—Doxorubicin—thyroid cancer	0.000207	0.000756	CcSEcCtD
Zoledronate—Malaise—Epirubicin—thyroid cancer	0.000206	0.000752	CcSEcCtD
Zoledronate—Vertigo—Epirubicin—thyroid cancer	0.000205	0.000749	CcSEcCtD
Zoledronate—Syncope—Epirubicin—thyroid cancer	0.000205	0.000748	CcSEcCtD
Zoledronate—Leukopenia—Epirubicin—thyroid cancer	0.000204	0.000747	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—thyroid cancer	0.000204	0.000746	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—thyroid cancer	0.000203	0.000742	CcSEcCtD
Zoledronate—Palpitations—Epirubicin—thyroid cancer	0.000202	0.000737	CcSEcCtD
Zoledronate—Loss of consciousness—Epirubicin—thyroid cancer	0.000201	0.000733	CcSEcCtD
Zoledronate—Cough—Epirubicin—thyroid cancer	0.000199	0.000728	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—thyroid cancer	0.000199	0.000727	CcSEcCtD
Zoledronate—GGPS1—Metabolism—TPR—thyroid cancer	0.000198	0.0107	CbGpPWpGaD
Zoledronate—Convulsion—Epirubicin—thyroid cancer	0.000198	0.000723	CcSEcCtD
Zoledronate—Hypertension—Epirubicin—thyroid cancer	0.000197	0.00072	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000196	0.000716	CcSEcCtD
Zoledronate—GGPS1—Metabolism—PRKAR1A—thyroid cancer	0.000195	0.0105	CbGpPWpGaD
Zoledronate—Anaemia—Doxorubicin—thyroid cancer	0.000195	0.000713	CcSEcCtD
Zoledronate—FDPS—Metabolism—NDUFA13—thyroid cancer	0.000195	0.0105	CbGpPWpGaD
Zoledronate—Arthralgia—Epirubicin—thyroid cancer	0.000194	0.00071	CcSEcCtD
Zoledronate—Myalgia—Epirubicin—thyroid cancer	0.000194	0.00071	CcSEcCtD
Zoledronate—Chest pain—Epirubicin—thyroid cancer	0.000194	0.00071	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—thyroid cancer	0.000194	0.000709	CcSEcCtD
Zoledronate—Anxiety—Epirubicin—thyroid cancer	0.000194	0.000708	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000193	0.000705	CcSEcCtD
Zoledronate—Discomfort—Epirubicin—thyroid cancer	0.000192	0.000702	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—thyroid cancer	0.00019	0.000696	CcSEcCtD
Zoledronate—Dry mouth—Epirubicin—thyroid cancer	0.00019	0.000694	CcSEcCtD
Zoledronate—Vertigo—Doxorubicin—thyroid cancer	0.00019	0.000693	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—thyroid cancer	0.000189	0.000692	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—thyroid cancer	0.000189	0.000691	CcSEcCtD
Zoledronate—Confusional state—Epirubicin—thyroid cancer	0.000188	0.000686	CcSEcCtD
Zoledronate—CA12—Metabolism—NDUFA13—thyroid cancer	0.000188	0.0101	CbGpPWpGaD
Zoledronate—Palpitations—Doxorubicin—thyroid cancer	0.000187	0.000682	CcSEcCtD
Zoledronate—Oedema—Epirubicin—thyroid cancer	0.000186	0.000681	CcSEcCtD
Zoledronate—Anaphylactic shock—Epirubicin—thyroid cancer	0.000186	0.000681	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—thyroid cancer	0.000186	0.000678	CcSEcCtD
Zoledronate—Infection—Epirubicin—thyroid cancer	0.000185	0.000676	CcSEcCtD
Zoledronate—Cough—Doxorubicin—thyroid cancer	0.000184	0.000673	CcSEcCtD
Zoledronate—Shock—Epirubicin—thyroid cancer	0.000183	0.00067	CcSEcCtD
Zoledronate—FDPS—Metabolism—CHST14—thyroid cancer	0.000183	0.00983	CbGpPWpGaD
Zoledronate—Convulsion—Doxorubicin—thyroid cancer	0.000183	0.000669	CcSEcCtD
Zoledronate—Nervous system disorder—Epirubicin—thyroid cancer	0.000183	0.000668	CcSEcCtD
Zoledronate—Thrombocytopenia—Epirubicin—thyroid cancer	0.000182	0.000666	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—thyroid cancer	0.000182	0.000666	CcSEcCtD
Zoledronate—Tachycardia—Epirubicin—thyroid cancer	0.000182	0.000664	CcSEcCtD
Zoledronate—Skin disorder—Epirubicin—thyroid cancer	0.000181	0.000661	CcSEcCtD
Zoledronate—Hyperhidrosis—Epirubicin—thyroid cancer	0.00018	0.000658	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—thyroid cancer	0.00018	0.000657	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—thyroid cancer	0.00018	0.000657	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—thyroid cancer	0.00018	0.000657	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—thyroid cancer	0.000179	0.000655	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000179	0.000652	CcSEcCtD
Zoledronate—Discomfort—Doxorubicin—thyroid cancer	0.000178	0.000649	CcSEcCtD
Zoledronate—Anorexia—Epirubicin—thyroid cancer	0.000178	0.000649	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000177	0.00951	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CHST14—thyroid cancer	0.000176	0.00948	CbGpPWpGaD
Zoledronate—Dry mouth—Doxorubicin—thyroid cancer	0.000176	0.000643	CcSEcCtD
Zoledronate—Hypotension—Epirubicin—thyroid cancer	0.000174	0.000636	CcSEcCtD
Zoledronate—Confusional state—Doxorubicin—thyroid cancer	0.000174	0.000635	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000172	0.00063	CcSEcCtD
Zoledronate—Oedema—Doxorubicin—thyroid cancer	0.000172	0.00063	CcSEcCtD
Zoledronate—Infection—Doxorubicin—thyroid cancer	0.000171	0.000626	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00017	0.00062	CcSEcCtD
Zoledronate—Shock—Doxorubicin—thyroid cancer	0.00017	0.00062	CcSEcCtD
Zoledronate—Nervous system disorder—Doxorubicin—thyroid cancer	0.000169	0.000618	CcSEcCtD
Zoledronate—CA14—Metabolism—HPGD—thyroid cancer	0.000169	0.00907	CbGpPWpGaD
Zoledronate—CA2—Metabolism—MINPP1—thyroid cancer	0.000169	0.00907	CbGpPWpGaD
Zoledronate—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000169	0.000617	CcSEcCtD
Zoledronate—Insomnia—Epirubicin—thyroid cancer	0.000168	0.000616	CcSEcCtD
Zoledronate—Tachycardia—Doxorubicin—thyroid cancer	0.000168	0.000615	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—thyroid cancer	0.000167	0.000612	CcSEcCtD
Zoledronate—Paraesthesia—Epirubicin—thyroid cancer	0.000167	0.000611	CcSEcCtD
Zoledronate—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000167	0.000609	CcSEcCtD
Zoledronate—Dyspnoea—Epirubicin—thyroid cancer	0.000166	0.000607	CcSEcCtD
Zoledronate—Somnolence—Epirubicin—thyroid cancer	0.000166	0.000605	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—thyroid cancer	0.000164	0.0006	CcSEcCtD
Zoledronate—Dyspepsia—Epirubicin—thyroid cancer	0.000164	0.000599	CcSEcCtD
Zoledronate—Decreased appetite—Epirubicin—thyroid cancer	0.000162	0.000592	CcSEcCtD
Zoledronate—FDPS—SREBP signalling—AKT1—thyroid cancer	0.000161	0.00868	CbGpPWpGaD
Zoledronate—Hypotension—Doxorubicin—thyroid cancer	0.000161	0.000589	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000161	0.000588	CcSEcCtD
Zoledronate—Fatigue—Epirubicin—thyroid cancer	0.000161	0.000587	CcSEcCtD
Zoledronate—Constipation—Epirubicin—thyroid cancer	0.000159	0.000582	CcSEcCtD
Zoledronate—Pain—Epirubicin—thyroid cancer	0.000159	0.000582	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000157	0.000574	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—thyroid cancer	0.000156	0.00057	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—thyroid cancer	0.000155	0.000566	CcSEcCtD
Zoledronate—Dyspnoea—Doxorubicin—thyroid cancer	0.000154	0.000561	CcSEcCtD
Zoledronate—Feeling abnormal—Epirubicin—thyroid cancer	0.000153	0.000561	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—thyroid cancer	0.000153	0.00056	CcSEcCtD
Zoledronate—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000152	0.000557	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—thyroid cancer	0.000152	0.000554	CcSEcCtD
Zoledronate—Decreased appetite—Doxorubicin—thyroid cancer	0.00015	0.000547	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000149	0.000544	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—thyroid cancer	0.000149	0.000543	CcSEcCtD
Zoledronate—GGPS1—Metabolism—SLC5A5—thyroid cancer	0.000149	0.00798	CbGpPWpGaD
Zoledronate—ABCC1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000148	0.00797	CbGpPWpGaD
Zoledronate—Urticaria—Epirubicin—thyroid cancer	0.000148	0.000541	CcSEcCtD
Zoledronate—FDPS—Metabolism—HPGD—thyroid cancer	0.000147	0.00793	CbGpPWpGaD
Zoledronate—Pain—Doxorubicin—thyroid cancer	0.000147	0.000539	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—thyroid cancer	0.000147	0.000539	CcSEcCtD
Zoledronate—Abdominal pain—Epirubicin—thyroid cancer	0.000147	0.000538	CcSEcCtD
Zoledronate—Body temperature increased—Epirubicin—thyroid cancer	0.000147	0.000538	CcSEcCtD
Zoledronate—CA2—Metabolism—NDUFA13—thyroid cancer	0.000143	0.00771	CbGpPWpGaD
Zoledronate—CA12—Metabolism—HPGD—thyroid cancer	0.000142	0.00764	CbGpPWpGaD
Zoledronate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000142	0.000519	CcSEcCtD
Zoledronate—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000141	0.000515	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000139	0.00748	CbGpPWpGaD
Zoledronate—Hypersensitivity—Epirubicin—thyroid cancer	0.000137	0.000501	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—thyroid cancer	0.000137	0.0005	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—thyroid cancer	0.000136	0.000498	CcSEcCtD
Zoledronate—Abdominal pain—Doxorubicin—thyroid cancer	0.000136	0.000498	CcSEcCtD
Zoledronate—CA2—Metabolism—CHST14—thyroid cancer	0.000135	0.00725	CbGpPWpGaD
Zoledronate—Asthenia—Epirubicin—thyroid cancer	0.000134	0.000488	CcSEcCtD
Zoledronate—Pruritus—Epirubicin—thyroid cancer	0.000132	0.000482	CcSEcCtD
Zoledronate—Diarrhoea—Epirubicin—thyroid cancer	0.000127	0.000466	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—thyroid cancer	0.000127	0.000464	CcSEcCtD
Zoledronate—GGPS1—Metabolism—RXRA—thyroid cancer	0.000125	0.00671	CbGpPWpGaD
Zoledronate—Asthenia—Doxorubicin—thyroid cancer	0.000124	0.000452	CcSEcCtD
Zoledronate—Dizziness—Epirubicin—thyroid cancer	0.000123	0.00045	CcSEcCtD
Zoledronate—Pruritus—Doxorubicin—thyroid cancer	0.000122	0.000446	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000121	0.00652	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00012	0.00643	CbGpPWpGaD
Zoledronate—Vomiting—Epirubicin—thyroid cancer	0.000118	0.000433	CcSEcCtD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000118	0.00635	CbGpPWpGaD
Zoledronate—Diarrhoea—Doxorubicin—thyroid cancer	0.000118	0.000431	CcSEcCtD
Zoledronate—Rash—Epirubicin—thyroid cancer	0.000117	0.000429	CcSEcCtD
Zoledronate—Dermatitis—Epirubicin—thyroid cancer	0.000117	0.000429	CcSEcCtD
Zoledronate—Headache—Epirubicin—thyroid cancer	0.000117	0.000426	CcSEcCtD
Zoledronate—Dizziness—Doxorubicin—thyroid cancer	0.000114	0.000416	CcSEcCtD
Zoledronate—Nausea—Epirubicin—thyroid cancer	0.000111	0.000404	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—thyroid cancer	0.00011	0.0004	CcSEcCtD
Zoledronate—CA2—Metabolism—HPGD—thyroid cancer	0.000109	0.00584	CbGpPWpGaD
Zoledronate—Rash—Doxorubicin—thyroid cancer	0.000109	0.000397	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—thyroid cancer	0.000109	0.000397	CcSEcCtD
Zoledronate—Headache—Doxorubicin—thyroid cancer	0.000108	0.000395	CcSEcCtD
Zoledronate—Nausea—Doxorubicin—thyroid cancer	0.000102	0.000374	CcSEcCtD
Zoledronate—CA14—Metabolism—TPR—thyroid cancer	9.69e-05	0.00521	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PRKAR1A—thyroid cancer	9.53e-05	0.00512	CbGpPWpGaD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	9.53e-05	0.00512	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—TPR—thyroid cancer	8.47e-05	0.00455	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PRKAR1A—thyroid cancer	8.33e-05	0.00448	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TRIM24—thyroid cancer	8.29e-05	0.00446	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—MINPP1—thyroid cancer	8.17e-05	0.00439	CbGpPWpGaD
Zoledronate—CA12—Metabolism—TPR—thyroid cancer	8.17e-05	0.00439	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PRKAR1A—thyroid cancer	8.04e-05	0.00432	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PPARG—thyroid cancer	7.88e-05	0.00424	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CHST14—thyroid cancer	7.8e-05	0.00419	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.55e-05	0.00406	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TRIM33—thyroid cancer	7.39e-05	0.00397	CbGpPWpGaD
Zoledronate—CA14—Metabolism—SLC5A5—thyroid cancer	7.25e-05	0.0039	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NDUFA13—thyroid cancer	6.95e-05	0.00373	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CHST14—thyroid cancer	6.53e-05	0.00351	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—TPR—thyroid cancer	6.45e-05	0.00347	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—CP—thyroid cancer	6.45e-05	0.00347	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.35e-05	0.00341	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—SLC5A5—thyroid cancer	6.34e-05	0.00341	CbGpPWpGaD
Zoledronate—CA2—Metabolism—TPR—thyroid cancer	6.24e-05	0.00336	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PTGS2—thyroid cancer	6.2e-05	0.00333	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PRKAR1A—thyroid cancer	6.14e-05	0.0033	CbGpPWpGaD
Zoledronate—CA12—Metabolism—SLC5A5—thyroid cancer	6.11e-05	0.00329	CbGpPWpGaD
Zoledronate—CA14—Metabolism—RXRA—thyroid cancer	6.1e-05	0.00328	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.94e-05	0.00319	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PTEN—thyroid cancer	5.41e-05	0.00291	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—RXRA—thyroid cancer	5.33e-05	0.00286	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—HPGD—thyroid cancer	5.26e-05	0.00283	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.18e-05	0.00278	CbGpPWpGaD
Zoledronate—CA12—Metabolism—RXRA—thyroid cancer	5.14e-05	0.00276	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TCF7L1—thyroid cancer	4.93e-05	0.00265	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.83e-05	0.0026	CbGpPWpGaD
Zoledronate—CA2—Metabolism—SLC5A5—thyroid cancer	4.67e-05	0.00251	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.27e-05	0.00229	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.06e-05	0.00218	CbGpPWpGaD
Zoledronate—CA2—Metabolism—RXRA—thyroid cancer	3.93e-05	0.00211	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PPARG—thyroid cancer	3.85e-05	0.00207	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TPR—thyroid cancer	3.61e-05	0.00194	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PRKAR1A—thyroid cancer	3.55e-05	0.00191	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MEN1—thyroid cancer	3.39e-05	0.00182	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PPARG—thyroid cancer	3.36e-05	0.00181	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PPARG—thyroid cancer	3.24e-05	0.00174	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—AKT1—thyroid cancer	3.12e-05	0.00167	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTGS2—thyroid cancer	3.03e-05	0.00163	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—TPR—thyroid cancer	3.02e-05	0.00162	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PRKAR1A—thyroid cancer	2.97e-05	0.0016	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CALCA—thyroid cancer	2.7e-05	0.00145	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.7e-05	0.00145	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTGS2—thyroid cancer	2.65e-05	0.00142	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTEN—thyroid cancer	2.64e-05	0.00142	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTGS2—thyroid cancer	2.55e-05	0.00137	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PPARG—thyroid cancer	2.48e-05	0.00133	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CDK1—thyroid cancer	2.45e-05	0.00131	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTEN—thyroid cancer	2.31e-05	0.00124	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—SLC5A5—thyroid cancer	2.26e-05	0.00122	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTEN—thyroid cancer	2.23e-05	0.0012	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.12e-05	0.00114	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NRG1—thyroid cancer	1.96e-05	0.00106	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTGS2—thyroid cancer	1.95e-05	0.00105	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—RXRA—thyroid cancer	1.9e-05	0.00102	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.85e-05	0.000994	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TERT—thyroid cancer	1.76e-05	0.000947	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTEN—thyroid cancer	1.7e-05	0.000914	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HIF1A—thyroid cancer	1.69e-05	0.000906	CbGpPWpGaD
Zoledronate—CA14—Metabolism—AKT1—thyroid cancer	1.52e-05	0.000818	CbGpPWpGaD
Zoledronate—ABCC1—Disease—BRAF—thyroid cancer	1.4e-05	0.00075	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—AKT1—thyroid cancer	1.33e-05	0.000715	CbGpPWpGaD
Zoledronate—CA12—Metabolism—AKT1—thyroid cancer	1.28e-05	0.000689	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PPARG—thyroid cancer	1.2e-05	0.000645	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PTGS2—thyroid cancer	1.13e-05	0.000606	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PTEN—thyroid cancer	9.83e-06	0.000529	CbGpPWpGaD
Zoledronate—CA2—Metabolism—AKT1—thyroid cancer	9.8e-06	0.000527	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTGS2—thyroid cancer	9.44e-06	0.000508	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NRAS—thyroid cancer	8.77e-06	0.000472	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTEN—thyroid cancer	8.24e-06	0.000443	CbGpPWpGaD
Zoledronate—ABCC1—Disease—KRAS—thyroid cancer	7.55e-06	0.000406	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HRAS—thyroid cancer	6.42e-06	0.000345	CbGpPWpGaD
Zoledronate—ABCC1—Disease—AKT1—thyroid cancer	5.67e-06	0.000305	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—AKT1—thyroid cancer	4.75e-06	0.000255	CbGpPWpGaD
